Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification.

ABSTRACT:

Background

An important mechanism that promoter methylation-mediated gene silencing for gene inactivation is identified in human tumorigenesis. Methylated genes have been found in breast cancer (BC) and beneficial biomarkers for early diagnosis. Prognostic assessment of breast cancer remain little known. Zinc finger protein 132 (ZNF132) is downregulated by promoter methylation in prostate cancer and esophageal squamous cell carcinoma. However, no study provides information on the status of ZNF132, analyzes diagnosis and prognostic significance of ZNF132 in BC.

Methods

In the present study, the expression of ZNF132 mRNA and protein level was determined based on the Cancer Genome Atlas (TCGA) RNA-Seq database and clinical samples analysis and multiple cancer cell lines verific

SUBMITTER: Liu Z 

PROVIDER: S-EPMC8028803 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature